The immunogenicity of protein therapeutics has so far proven to be difficult to predict in
patients, with many biologics inducing undesirable immune responses that are directed …

Key issues for prostate cancer patients are the detection of recurrent disease and the
treatment of metastasized cancer. Early detection is a major challenge for all conventional …

Despite encouraging clinical results with next generation drugs (MDV3100 and abiraterone)
that inhibit androgen receptor (AR) signaling in patients with castration-resistant prostate …

Background Prostate cancer is radiosensitive. Prostate‐specific membrane antigen (PSMA)
is selectively overexpressed on advanced, castration‐resistant tumors. Lutetium‐177 …

Conventional external-beam radiation therapy is dedicated to the treatment of localized
disease, whereas radioimmunotherapy represents an innovative tool for the treatment of …

Purpose: Standard imaging for assessing osseous metastases in advanced prostate cancer
remains focused on altered bone metabolism and is inadequate for diagnostic, prognostic …

The prostate-specific membrane antigen (PSMA) is a molecular target whose use has
resulted in some of the most productive work toward imaging and treating prostate cancer …

The present article highlights the important progress made in the last two decades in the
fields of molecular imaging and radionuclide therapy. Advancements in radiometal-based …

Selection of the right drug for the right patient is a promising approach to increase clinical
benefit of targeted therapy with monoclonal antibodies (mAbs). Assessment of in vivo …

We conducted a phase I dose-escalation study with 89Zr-desferrioxamine-IAB2M (89Zr-
IAB2M), an anti–prostate-specific membrane antigen minibody, in patients with metastatic …